MedTrace Logo

Role of the ATP7A Transporter in Ovarian Cancer

NCT05490407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-01-30

No results posted yet for this study

Summary

Ovarian cancer has the highest mortality rate among all gynecologic cancers, with most patients presenting with advanced stage tumors. About a third of patients do not respond to primary platinum-based chemotherapy treatment, and over time up to 80 % of others develop chemoresistance, rendering recurrent disease incurable. Despite all the studies published in the literature, it has not been proven that the number of cells with expressed ATP7A in certain tumors increases independently of the therapy. In addition, no study has been conducted on a sample of patients with confirmed serous histology of ovarian cancer only. The aim of the study is to demonstrate increased expression of the ATP7A transporter in cells resistant to carboplatin.

Conditions

  • Gynecologic Cancer
  • Ovarian Cancer
  • High Grade Serous Carcinoma
  • Chemotherapy Effect

Interventions

DRUG

Carboplatin

Patients will receive neoadjuvant chemotherapy according to ESGO guidelines

Sponsors & Collaborators

  • University of Ljubljana, Faculty of Medicine, Institute of Pharmacology and Experimental Toxicology

    collaborator UNKNOWN

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Borut Kobal, MD; PhD · Department of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Center

  • Katarina Černe, MD, PhD · Institute of Pharmacology and Experimental Toxicology, Medical Faculty, University Ljubljana

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2023-05-01
Completion
2024-01-01

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490407 on ClinicalTrials.gov